Skip to main content

You must have JavaScript enabled in order to access this part of the site. Please enable JavaScript and then reload this page in order to continue.

Changes to Hepatitis C Agents Drug Class Effective January 2026

Last updated on

On January 1, 2026, the status of drugs in the hepatitis C agents class will change based on the recommendations from the Texas Drug Utilization Review Board meeting that was held on October 24, 2025.

Mavyret, Texas Medicaid’s preferred direct-acting antiviral drug option for treating hepatitis C infection, will no longer be the preferred drug.

Email vdp-formulary@hhs.texas.gov with comments or any questions.